Copyright
©The Author(s) 2021.
World J Clin Cases. Apr 16, 2021; 9(11): 2533-2541
Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2533
Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2533
Variable | On presentation | Reference range |
Blood routine examination | ||
White blood cell count | 6.69 × 109/L | 3.5-9.5 × 109/L |
Neutrophils | 5.33 × 109/L | 1.8-6.3 × 109/L |
Lymphocytes | 1.02 × 109/L | 1.1-3.2 × 109/L |
Monocytes | 0.31 × 109/L | 0.1-0.6 × 109/L |
Eosinophils | 0.01 × 109/L | 0.02-0.52 × 109/L |
Basophils | 0.02 × 109/L | 0-0.06 × 109/L |
Hemoglobin | 124 g/L | 115-150 g/L |
Platelet | 161 × 109/L | 125-350 × 109/L |
Sodium | 147 mmol/L | 137-147 mmol/L |
Potassium | 2.9 mmol/L | 3.5-5.3 mmol/L |
Chloride | 105 mmol/L | 99-110 mmol/L |
Calcium | 2.62 mmol/L | 2.11-2.52 mmol/L |
Albumin | 44.9 g/L | 20-55 g/L |
Aspartate aminotransferase | 23 U/L | 13-35 U/L |
Alanine aminotransferase | 17 U/L | 7-40 U/L |
Bilirubin | 18.91 μmol/L | 3-22 μmol/L |
Creatinine | 81 μmol/L | 31-132 μmol/L |
Urea nitrogen | 3.12 mmol/L | 2.6-7.5 mmol/L |
Cystatin c | 0.88 mg/L | 0.10-0.45 mg/L |
Variable | Reference range | First visit | Second hospitalisation | Third hospitalisation | Forth hospitalisation | Last dose of chemotherapy |
CEA (ng/mL) | 0-3.4 | 44.04 | 28.69 | 17.18 | 5.67 | 3.21 |
CA242 (IU/mL) | 0-15 | 18.08 | 14.45 | 10.81 | 7.85 | 8.52 |
CA19-9 (U/mL) | 0-39 | 100.8 | 60.81 | 33.83 | 18.39 | 16.70 |
AFP (ng/mL) | 0-7.02 | 9.03 | 8.09 | 7.16 | 6.15 | 6.75 |
CA15-3 (U/mL) | 0-25 | 30.37 | 22.58 | 20.13 | 15.84 | 14.70 |
CA125 (U/mL) | 0-35 | 137.4 | 40.68 | 21.11 | 11.66 | 12.10 |
HE4 (pmol/L) | < 140 | 105.7 | 72.3 | 70.1 | 64.4 | 50.7 |
Gene | Variation | Mutation | Cervical lymph node | Cervical neoplasm | Peripheral Blood |
Tumor-specific mutation | |||||
CCNE1 | Gene amplification | - | 3.1-fold | - | |
DLL3 | Gene amplification | - | 3.2-fold | - | |
KRAS | Gene amplification | 5.2-fold | 9.8-fold | - | |
PTK2 | Gene amplification | - | 2.2-fold | - | |
RB1 | Splice site mutation | c.1421+29_1498+69del | 8.5% | 52.0% | 0.4% |
STK11 | Single copy deletion | - | Single copy deletion | - | |
VHL | Single copy deletion | - | Single copy deletion | - | |
DDR2 | Truncation mutation | c.1646C>G(p.S549*) | 10.4% | 20.8% | 0.8% |
EPHA3 | Missense mutation | c.2515G>A(p.E839K) | - | 1.1% | - |
ETV6 | Missense mutation | c.369G>C(p.Q123H) | 14.0% | 23.5% | 0.9% |
GNAS | Missense mutation | c.1984G>A(p.E662K) | 13.4% | - | 0.6% |
TAP1 | Missense mutation | c.149C>T(p.P50L) | 2.0% | - | - |
TP53 | Splice site mutation | c.376-1G>A | 18.2% | 69.9% | 0.8% |
TP53 | Single copy deletion | - | - | Single copy deletion | - |
Germline mutation | Mutation | ||||
BRCA2 | Truncation mutation | c.8629G>T(p.E2877*) | |||
EPCAM | Frameshift mutation | c.843delT(p.G282Efs*21) |
- Citation: Wang Q, Niu XY, Feng H, Wu J, Gao W, Zhang ZX, Zou YW, Zhang BY, Wang HJ. Gastrointestinal-type chemotherapy prolongs survival in an atypical primary ovarian mucinous carcinoma: A case report. World J Clin Cases 2021; 9(11): 2533-2541
- URL: https://www.wjgnet.com/2307-8960/full/v9/i11/2533.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i11.2533